Prospective nationwide (UK) audit, including 1257 patients who received exenatide as add-on to insulin Follow up, 12 months Addition of exenatide to patients continuing insulin resulted in: HbA1c reduction of 0.5%Weight reduction of 5.8 kgAn insulin dose reduction of 42 units per day, and an insulin discontinuation rate of 16.6%Patients receiving both exenatide + insulin experienced more hypoglycaemia than those receiving exenatide without insulin. This evidence concerns the gene INS and Hypoglycemia.